How Analysts Rated Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Last Week?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Logo

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Ratings Coverage

Among 5 analysts covering Aurinia Pharmaceuticals (NASDAQ:AUPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aurinia Pharmaceuticals has $24 highest and $11 lowest target. $15’s average target is 127.62% above currents $6.59 stock price. Aurinia Pharmaceuticals had 9 analyst reports since March 19, 2019 according to SRatingsIntel. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, March 19. Raymond James maintained the shares of AUPH in report on Wednesday, March 20 with “Outperform” rating. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, March 20 report. H.C. Wainwright maintained Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) on Wednesday, March 20 with “Buy” rating. Below is a list of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) latest ratings and price target changes.

10/09/2019 Broker: Oppenheimer Rating: Outperform New Target: $14.0000 Initiates Coverage On
24/04/2019 Broker: BidaskScore Rating: Sell Downgrade
12/04/2019 Broker: BidaskScore Rating: Sell Downgrade
05/04/2019 Broker: BidaskScore Rating: Hold Upgrade
21/03/2019 Broker: Mackie Rating: Buy Maintain
20/03/2019 Broker: Raymond James Rating: Outperform Old Target: $9 New Target: $11 Maintain
20/03/2019 Broker: RBC Capital Markets Rating: Buy New Target: $11 Maintain
20/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $15 Maintain
19/03/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $24 Maintain

The stock increased 2.17% or $0.14 during the last trading session, reaching $6.59. About 484,554 shares traded or 6.39% up from the average. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has risen 19.77% since September 13, 2018 and is uptrending. It has outperformed by 19.77% the S&P500.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company has market cap of $607.73 million. The firm is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It currently has negative earnings. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc.

More notable recent Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) news were published by: Benzinga.com which released: “80 Biggest Movers From Yesterday – Benzinga” on September 11, 2019, also Finance.Yahoo.com with their article: “Hedge Funds Have Never Been More Bullish On Aurinia Pharmaceuticals Inc (AUPH) – Yahoo Finance” published on June 28, 2019, Business.Financialpost.com published: “Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference – Financial Post” on September 06, 2019. More interesting news about Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were released by: Finance.Yahoo.com and their article: “Here’s What Hedge Funds Think About Aurinia Pharmaceuticals Inc (AUPH) – Yahoo Finance” published on May 09, 2019 as well as Seekingalpha.com‘s news article titled: “Aurinia And Voclosporin In Lupus Nephritis: The Countdown Begins – Seeking Alpha” with publication date: August 29, 2019.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.